Beyond Air, Inc. — Form 8-K
Filed August 18, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Beyond Air secured up to $30.1M in financing ($10.2M upfront + $20M in warrant exercises, including $10M tied to FDA approval of second-generation LungFit PH) from institutional healthcare investors and insiders. Q2 2026 revenue was $1.8M (flat YoY); company reaffirms $8M FY2026 guidance and $16–18M FY2027 guidance (>110% growth). Key milestones: third major U.S. GPO agreement expanding hospital reach by ~2,000 facilities; distribution now covers 45+ countries; PMA supplement for second-gen device under FDA review with approval expected 2H 2026.
Why this rating
Financing is ~194% of market cap ($30.1M vs $15.5M), materially extends runway. Yet flat Q2 revenue, $7.9M quarterly loss, and FDA approval risk limit immediate upside. Significant but conditional.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.